

DAFTAR PUSTAKA

- Ahmedin, J. Siegel, R. Xu, J. and Ward, E. 2010. Cancer Statistics. *CA Cancer Clin.* 60:277–300.
- American Cancer Society. *Global Cancer Fact & Figures (2nd Edition)*. 2011. American Cancer Society. Atlanta GA. USA.
- Arany, Z. Huang, L.E. Eckner, R. Bhattacharya, S. Jiang, C. Goldberg M.A. Bunn, H.F. and Livingston, D.M. 1996. An essential role for p300/CBP in the cellular response to hypoxia. *Proc Natl Acad Sci.* USA. 93:12969-12973.
- Aziz, F.M. 2009. Gynecological Cancer in Indonesia. *J Gynecol Oncol.* 20(1):pp.8-10.
- Babar, I.A.J. Czocor, A. Steinmetz, J. B. Weidhaas, P.M. Glazer, and Slack, F.J. 2011. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. *Cancer Biology & Therapy.* USA. 12(10):908–914.
- Becker, C. A. Hammerle-Fickinger, I. Riedmaier, M.W. Pfaffl. 2010. mRNA and microRNA quality control for RT-qPCR analysis. *Methods* 50: 237-243.
- Behm-Ansmant, I. Rehwinkel, J. Doerks, T. Stark, A. Bork, P. and Izaurralde, E. 2006. mRNA degradation by mikroRNAs and gw182 Requires Both ccr4: not deadenylase and dcp1: Dcp2 decapping complexes. *Genes Dev.* 20: 1885-1898.
- Bell, E.L. Emerling, B.M. Ricoult, S.J. and Guarente, L. 2011. SirT3 suppresses hypoxia inducible factor 1 alpha and tumor growth by inhibiting mitochondrial ROS production. *Oncogene.* 30:2986-2996.
- Bhattacharya, S. Michels, C.L. Leung, M.K. Arany, Z.P. Kung, A.L. and Livingston, D.M. 1999. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. *Genes Dev.* 13: 64–75.
- Birner, P. Schindl, M. Obermair, A. and Breitenecker, G. 2001. Expression of hypoxia inducible factor 1 α in epithelial ovarian tumors its impact on prognosis and on response to chemotherapy. *Clin Cancer Res.* 7(6):1661-1668.
- Birner, P. Schindl, M. Obermair, A. Breitenecker, G. and Oberhuber, G. 2001. Expression of Hypoxia-inducible Factor 1 α in Epithelial Ovarian Tumors: Its Impact on Prognosis and on Response to Chemotherapy. *Clin Cancer Res.* (7):1661–1668.

- Brahimi-Horn, C. Mazure, N. and Pouyssegur, J. 2005. Signalling via the hypoxia inducible factor-1alpha requires multiple posttranslational modifications. *Cell Signal.* (17):1–9.
- Brennecke, J. Stark, A. Russell, R.B. and Cohen, S.M. 2005. Principles of microRNA-Target Recognition. *PLoS Biol.* 3:85.
- Brizel, D.M. Dodge, R.K. Clough, R.W. and Dewhirst, M.W. 1999. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. *Radiother Oncol.* 53: 113–117.
- Brown, J.M. and Wilson, W.R. 2004. Exploiting tumour hypoxia in cancer treatment. *Nat Rev Cancer.* 4:437-47.
- Bruning, U. Cerone, L. Neufeld, Z. and Fitzpatrick, S.F. 2011. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1 activity during prolonged hypoxia. *Mol and Cell Bio.* 31(19):4087–4096.
- Calore, F. and M. Fabbri. 2011. MicroRNAs and Cancer. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 1-20.
- Carbia-Nagashima, A. Gerez, J. Perez-Castro, C. Paez-Pereda, M. Silberstein, S. Stalla, G.K. Holsboer, F. and Arzt, E. 2007. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. *Cell.* 131:309-323.
- Cheng, G. 2015. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. *Adv Drug Del Rev.* (81):75–93.
- Cheng, J. Kang, X. Zhang, S. and Yeh, E.T. 2007. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. *Cell.* 131: 584–595.
- Cheng, L.L. Hui, N. Ming, W. Li, P.S. Jian, Fang, L. Ying, Y. Y. Min, Y. Qin, L. Q. Zheng, G. Z. and Bing, Y. L. 2012. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. *Oncol Rep.* 27: 1960-1966.
- Chinen, T. Komai, K. and Muto, G. 2011. Prostaglandin E2 and HIF1A have a role in intestinal immune tolerance. *Nature Commun.* 2:190.
- Christofk, H.R. Vander-Heiden, M.G. Harris, M.H. Ramanathan, A. Gerszten, R.E. Wei, R. Fleming, M.D. Schreiber, S.L. and Cantley, L.C. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature.* 452: 230–233.

- Conde, E. Laura, A. Ignacio, B.S. David, S.M. Elia, A.F. Bele'n, P. Edurne, R. Ana, S. Carlos, J. Angel, O. Manuel, L.C. Luis-del, P. Manuel, O. de, L. Fernando, L. Rafael, S. Jose, A.S. Tomero, and Mari'a L.G.B. 2012. Hypoxia inducible factor 1-alpha (HIF-1 Alpha) is induced during reperfusion after renal ischemia and is critical for proximal tubule cell survival. *Plos One*. 7(3):33258.
- Crews, S.T. 1998. Control of cell lineage-specific development and transcription by bHLH-PAS proteins. *Genes Dev*. 12:607-620.
- Cui, J.J. B. Eldredge, Y. Xu, and D. Puett. 2011. MicroRNA Expression and Regulation in Human Ovarian Carcinoma Cells by Luteinizing Hormone. *PLoS ONE*. 6(7): 1-10.
- D'urso, P.I. Oscar, F.D. Carlo, S. Massimo, M. Cosimo, D.G. Antonio, M. Antonia, C. Caliandro, P. and Santo, M. 2012. miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. *Oncology*. 41: 228-234.
- Dahiya, N. Sherman-Baust, C.A. Wang, T.L. and Davidson, B. 2008. MicroRNA expression and identification of putative miRNA targets in ovarian cancer Jörg Hoheisel (ed.). *PLoS ONE*. 3(6):e2436.
- Daponte, A. Ioannou, M. Mylonis, I. and Simos, G. 2008. Prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study. *BMC Cancer*. 8(1):335.
- Davis, B.N., Hilyard, A.C., Lagna, G., Hata, A., 2008. SMAD proteins control DROSHA-mediated microRNA maturation. *Nature*. 454:56-61.
- Dioum, E.M. Chen, R. Alexander, M.S. Zhang, Q. Hogg, R.T. Gerard, R.D. and Garcia, J.A. 2009. Regulation of hypoxia-inducible factor 2 alpha signaling by the stress-responsive deacetylase sirtuin 1. *Science*. 324: 1289-1293.
- Du, Z.M. Hu, L.F. Wang, H.Y. Yan, L.X. Zeng, Y.X. Shao, J.Y. and Ernberg, I. 2011. Upregulation of miR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. *PLoS One*. 6(4): e19137.
- Ema, M. Hirota, K. Mimura, J. Abe, H. Yodoi, J. Sogawa, K. Poellinger, L. and Fujii-Kuriyama, Y. 1999. Molecular mechanisms of transcription activation by HLF and HIF1 alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/ p300. *EMBO*. 18: 1905-1914.

- Epstein, A.C. Gleadle, J.M. McNeill, L.A. Hewitson, K.S. O'Rourke, J. Mole, D.R. Mukherji, M. Metzen, E. Wilson, M.I. Dhanda, A. Tian, Y.M. Masson, N. Hamilton, D.L. Jaakkola, P. Barstead, R. Hodgkin, J. Maxwell, P.H. Pugh, C.W. Schofield, C.J. and Ratcliffe, P.J. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell*. 107:43–54.
- Fabian, M.R. Sonenberg, N. and Filipowicz, W. 2010. Regulation of mRNA Translation and Stability by microRNAs. *Annu Rev Biochem*. 79:351–379.
- Falcone, G. Felsani, A. and D'Agnano, I. 2015. Signaling by exosomal microRNAs in cancer. *Journal of Experimental & Clinical Cancer Research*. 34(32):1-10.
- Ferlay, J. Soerjomataram, I. Ervik, M. Dikshit, R. Eser, S.C. Mathers, M. Rebelo, M. Parkin, D.M. Forman, D. and Bray, F. 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Globocan. *ARC Cancer Base*. Diakses dari <http://www.iarc.fr/en/publications/eresources/cancerbases/>.
- Gao, F. Chang, J. Wang, H. and Zhang, G. 2014. Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. *Oncol Rep*. 31(1):351.
- George, G.P. and Mittal, R.D. 2010. microRNAs: Potential biomarker in cancer. *Clin Biochem*. 1:4-14.
- GLOBOCAN, 2012. *Estimated cancer incidence, mortality, and prevalence worldwide in 2012*. Diakses dari <http://globocan.iarc.fr/Pages/online.aspx>
- Goff, B.A. L. Mandel, H.G. Muntz, and C. H. Melancon. 2000. Ovarian Carcinoma Diagnosis Results of a National Ovarian Cancer Survey. *American Cancer Society*. 89 (10):1-8.
- Goldberg, M.A. Dunning, S.P. and Bunn, H.F. 1988. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. *Science*. 242:1412-1415.
- Gu, Y.Z. Moran, S.M. Hogenesch, J.B. Wartman, L. and Bradfield, C.A. 1998. Molecular characterization and chromosomal localization of a third alpha class hypoxia inducible factor subunit, HIF3 alpha. *Gene Expr*. 7:205-213.
- Hara, S. Hamada, J. Kobayashi, C. Kondo, Y. and Imura, N. 2001. Expression and characterization of hypoxia-inducible factor (HIF)-3 alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3 alpha. *Biochem Biophys Res Commun*. 287:808–813.

- Hitosugi, T. Kang, S. Vander, H.M.G. Chung, T.W. Elf, S. Lythgoe, K. Dong, S. Lonial, S. Wang, X. Chen, G.Z. Xie, J. Gu, T.L. Polakiewicz, R.D. Roesel, J.L. Boggon, T.J. Khuri, F.R. Gilliland, D.G. Cantley, L.C. Kaufman, J. and Chen, J. 2009. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. *Science*. 1-8.
- Huang, C. Han, Y. Wang, Y. Sun, X. Yan, S. Yeh, E.T. Chen, Y. Cang, H. Li, H. Shi, G. Cheng, J. Tang, X. and Yi, J. 2009. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. *EMBO*. 28:2748-2762.
- Huang, L.E. Arany, Z. Livingston, D.M. and Bunn, H.F. 1996. Activation of hypoxia inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. *Biol Chem*. 271:32253-32259.
- Huang, L.E. Gu, J. Schau, M. and Bunn, H.F. 1998. Regulation of hypoxia inducible factor 1alpha is mediated by an O₂-dependent degradation domain via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci. USA*. 95:7987-7992.
- Huang. 2013. Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through HIF1A.1(9).
- Ivan, M. Kondo, K. Yang, H. Kim, W. Valiando, J. Ohh, M. Salic, A. Asara, J.M. Lane, W.S. Kaelin, and Jr, W.G. 2001. HIF alpha targeted for VHL mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science*. 292:464-468.
- Jaakkola, P. Mole, D.R. Tian, Y.M. Wilson, M.I. Gielbert, J. Gaskell, S.J. Kriegsheim, A. Hebestreit, H.F. Mukherji, M. and Schofield, C.J. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. *Science*. 292:468-472.
- Jackson, A.L. Bartz, S.R. and Schelter, J. 2003. Expression profiling reveals off-target gene regulation by RNAi. *Nat Biotechnol*. 21:635.
- Jansson, M.D. and Lund, A.H. 2012. MicroRNA and cancer. *Mol Oncol*. 590e6 10.
- Jansson, M.D. and A. H. Lund. 2012. MicroRNA and cancer. *Molecular Oncology* 6: 590-610.
- Jelovac, D. and Armstrong, D.K. 2011. Recent Progress in the Diagnosis and treatment of Ovarian Cancer. *Ca Cancer J Clin*. 61: pp.183–203.

- Ji, W. Zhang, X. Sun, X. and Wang, X. 2014. miRNA-155 modulates the malignant biological characteristics of NK/T-cell lymphoma cells by targeting FOXO3a gene. *Medical Sciences*. 34(6):882-888.
- Kaelin, J.W.G. and Ratcliffe, P.J. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell*. 30:393-402.
- Kaku, T. Ogawa, S. Kawano, Y. Ohishi, Y. Kobayashi, H. Hirakawa, T. and Nakano, H. 2003. Histological classification of ovarian cancer. *Med Electron Microsc.* (36):9–17.
- Kallio, P.J. Pongratz, I. Gradin, K. McGuire, J. and Poellinger, L. 1997. Activation of hypoxia-inducible factor 1 alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. *Proc Natl Acad Sci. USA*. 94:5667-5672.
- Katz, B. Claes G. Trope, R. Reich, and B. Davidson. 2015. MicroRNAs in Ovarian Cancer. *Human Pathology*. Xx:1-12.
- Ke, Q. and Costa, M. 2006. Hypoxia-inducible factor-1 (HIF-1). *Mol Phar.* 70(5):1469-1480.
- Kinose, Y. Sawada, K. Nakamura, K. and Kimura, T. 2014. The Role of MicroRNAs in Ovarian Cancer. *BioMed Research Intern*. 1-11.
- Krol, J. Loedige, I. and Filipowicz, W. 2010. The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet*. 11(9):597-610.
- Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., Jacks, T. 2007. Impaired microRNA processing enhances cellular.
- Lando, D. Peet, D.J. Gorman, J.J. Whelan, D.A. Whitelaw, M.L. and Bruick, R.K. 2002a. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia -inducible factor. *Genes Dev*. 16:1466-1471.
- Lando, D. Peet, D.J. Whelan, D.A. Gorman, J.J. and Whitelaw, M.L. 2002b. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. *Science*. 295:858-861.
- Lao, G. Liu, P. Wu, Q. and Zhang, W. 2014. Mir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1. *Tum Bio*. 35(12):11933-11938.
- Laura, M.S. Seeber, A. Horr e, N.A. Marc, A.G.G. Vooijs, A. Peter, M. Heintz,

- Wall, E.V. D. René, H.M. Verheijen, P. J. and Diest, V. 2011. The role of hypoxia inducible factor-1alpha in gynecological cancer. *Critical Rev in Oncol/Hematol.* (78):173-184.
- Leitner, A. 2009. *MicroRNA Target Prediction: Institute of Genomic and Bioinformatics.* Graz University of Technology.
- Li, C. Nie, H. Wang, M. Sui, L. Li, J. Yui, Y. Yan, M. Qu, Q. Zhu, Z. and Liu, B. 2012. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. *Oncol Rep* 27:1960-1966.
- Li, T. Yang, J. Lv, X. and Liu, K. 2014. miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. *Biotech Lett.* 36 (9):1743-1752.
- Lingel, A. Simon, B. Izaurralde, E. and Sattler, M. 2003. Structure and nucleic-acid binding of the Drosophila argonaute 2 PAZ domain. *Nature.* 426: 465-469.
- Liu, B.Y. 2012a. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. *Oncol Rep.* 1-6.
- Liu, Michelle, X. Chan, David, W. Ngan, and Hextan, Y.S. 2012. Mechanisms of chemoresistance in human ovarian cancer at a glance. *Gyne Obstet.* 2:3.
- Liu, Z. 2012b. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. *Oncol Lett.* 1-7.
- Lodes, M.J. Caraballo, M. Suci, D. Munro, S. Kumar, A. and Anderson, B. 2009. Detection of cancer with serum mikroRNAs on an oligonucleotide Microarray. *PloS One.* 4:e6229.
- Lombard, D.B. Alt, F.W. Cheng, H.L. Bunkenborg, J. Streeper, R.S. Mostoslavsky, R. Kim, J. Yancopoulos, G. Valenzuela, D. Murphy, A. Yang, Y. Chen, Y. Hirsche, M.D. Bronson, R.T. Haigis, M. Guarente, L.P. Farese, J.R.V. Weissman, S. Verdin, E. and Schwer, B. 2007. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. *Mol Cell Biol.* 27:8807-8814.
- Luo, W. Hu, H. Chang, R. Zhong, J. Knabel, M. O'Meally, R. Cole, R.N. Pandey, A. and Semenza, G.L. 2011. Pyruvate kinase M2 is a PHD3- stimulated coactivator for hypoxia-inducible factor 1. *Cell.* 145:732-744.
- Lv, Z. Fan, Y. Chen, H. and Zhao, D. 2015. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. *Tum Bio.*

36(3):1619-1625.

- Makino, Y. Kanopka, A. Wilson, W.J. Tanaka, H. and Poellinger, L. 2002. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3 alpha locus. *Biol Chem.* 277:32405-32408.
- Masson, N. Singleton, R.S. Sekirnik, R. Trudgian, D.C. Ambrose, L.J. Miranda, M.X. Tian, Y.M. Kessler, B.M. Schofield, C.J. and Ratcliffe, P.J. 2012. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. *EMBO Rep.* 13:251-257.
- Masson, N. Willam, C. Maxwell, P.H. Pugh, C.W. and Ratcliffe, P.J. 2001. Independent function of two destruction domains in hypoxia inducible factor-alpha chains activated by prolyl hydroxylation. *EMBO.* 20:5197-5206.
- Maxwell, P.H. Wiesener, M.S. Chang, G.W. Clifford, S.C. Vaux, E.C. Cockman, M.E. Wykoff, C.C. Pugh, C.W. Maher, E.R. and Ratcliffe, P.J. 1999. The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis. *Nature.* 399:271-275.
- Maynard, M.A. Qi, H. Chung, J. Lee, E.H. Kondo, Y. Hara, S. Conaway, R.C. Conaway, J.W. and Ohh, M. 2003. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. *Biol Chem.* 278:11032-11040.
- Melo, S.A., Moutinho, C., Ropero, S., Calin, G.A., Rossi, S., Spizzo, R., Fernandez, A.F., Davalos, V., Villanueva, A., Montoya, G., Yamamoto, H., Schwartz Jr., S., Esteller, M., 2010. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. *Cancer Cell.* 18:303-315.
- Melo, S.A., Ropero, S., Moutinho, C., Aaltonen, L.A., Yamamoto, H., Calin, G.A., Rossi, S., Fernandez, A.F., Carneiro, F., Oliveira, C., Ferreira, B., Liu, C.G., Villanueva, A., Capella, G., Schwartz Jr., S., Shiekhatar, R., Esteller, M., 2009. A TARBP2 mutation in human cancer mpairs microRNA processing and DICER1 function. *Nat. Genet.* 41: 365-370.
- Menor, M., Ching, T., Zhu, X., Garmire, D., and Garmire, LX. 2014. mirMark: a site-level and UTR-level classifier for miRNA target prediction. *Genome Biology.* 15: pp.500.
- Nakamura, K. Sawada, K. Yoshimura, A. Kinose, Y. Nakatsuka, E. and Kimura, T. 2016. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. *Molecular Cancer.* 15(48):1-10.

- Nakamura, M. 2013. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. *Onco Reps.* 2-9.
- Newman, M.A., Hammond, S.M., 2010. Emerging paradigms of regulated microRNA processing. *Genes Dev.* 24: 1086-1092.
- Nguyen, L. Cardenas, G. Segundo, J. Gordon, P. Curtin, C. Momeni, M. Chuang, L. and Fishman, D. 2013. Biomarkers for early detection of ovarian cancer. *Women's Health.* 9(2):171-187.
- Polytarchou, Christos, Iliopoulos, D. Hatziapostolou, M. Kottakis, F. Maroulakou, I. Struhl, K. and Tsihchlis, P.N. 2011. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. *Cancer Res.* 71(13): 4720–4731.
- Prat, J. 2012. New insights into ovarian cancer pathology. *Annals of Oncol* 23 (Supp 10):x111–x117.
- Pugh, C.W. O'Rourke, J.F. Nagao, M. Gleadle, J.M. and Ratcliffe, P.J. 1997. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. *Biol Chem.* 272:11205-11214.
- Qin, W. Ren, Q. Liu, T. and Huang, Y. 2013. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. *FEBS Letters.* 587(9):1434-1439.
- Ren, Y. Gao, J. Liu, J.Q. Wang, X.W. Gu, J. Huang, H. Gong, Y. and Li, Z. 2012. Differential signature of fecal microRNAs in patients with pancreatic cancer.
- Resnick, K.E. Alder, H. Hagan, J.P. and Richardson, D.L. 2009. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. *Gyne Onco.* 112(1):55-59.
- Robert, F.O. 2002. Recurrent ovarian cancer: evidence-based treatment. *Clin Onco.* 20(5):1161-1163.
- Rothschild, S.I. 2014. microRNA therapies in cancer. *Mol and Cel Ther.* 2(1):7.
- Ruan, K. Song, G. and Ouyang, G. 2009. Role of hypoxia in the hallmarks of human cancer. *Cell Biochem.* 107:1053-62.
- Rusnita, T. dan Prijono, I. Ekspresi P53, Bcl-2 dan Nm23-H1 pada Karsinoma Ovarium Tipe Serosum dan Musinosum serta Hubungannya dengan Stadium dan Derajat Histologi. *Majalah Patologi.* 23(2): 13-19.

- Salceda, S. and Caro, J. 1997. Hypoxia-inducible factor 1 α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hipoksia depends on redox-induced changes. *Biol Chem.* 272:22642-22647.
- Semenza, G.L. 1998. Hypoxia-inducible factor 1: master regulator of O₂ homeostasis. *Curr Opin Genet Dev.* 8:588-594.
- Semenza, G.L. 2010. HIF-1: upstream and downstream of cancer metabolism. *Curr Opin Genet Dev.* 20(1): 51.
- Semenza, G.L. Nejfelt, M.K. Chi, S.M. and Antonarakis, S.E. 1991. Hypoxia-inducible nuclear factors bind to an enhancer element located 3 to the human erythropoietin gene. *Proc Natl Acad Sci. USA.* 88: 5680-5684.
- Shibuya, H. Inuma, H. Shimada, R. Horiuchi, A. and Watanabe, T. 2010. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. *Onco.* 79(3-4):313-20.
- Soslow, A. and Robert. 2008. Histologic Subtypes of Ovarian Carcinoma: An Overview. *International Journal of Gynecological Pathology.* 27: 161–174.
- Srinivas, V. Zhang, L.P. Zhu, X.H. and Caro, J. 1999. Characterization of an oxygen/ redox-dependent degradation domain of hypoxia-inducible factor alpha (HIFalpha) proteins. *Biochem Biophys Res Commun.* 260:557-561.
- Suzuki, H., Maruyama, R., Yamamoto, E., and Kai, M. 2012. DNA methylation and microRNA dysregulation in cancer. *Molecular oncology.* 6: 567-578.
- Tan, Z.Q. Liu, F.X. Tang, H.L. and Su, Q. 2010. Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer. 45(10):772.
- Textoris, J. Beaufils, N. Quintana, G. and Lassoud, A.B. 2012. Hypoxia-inducible factor (HIF1a) gene expression in human shock states. In: *Intensive care medicine.* Springer 233 Spring ST. 10013 USA. Pp: 88.
- Tinelli, A. Vergara, D. Martignago, R. Leo, G. Pisanò, M. and Malvasi, A. 2009. An Outlook on Ovarian Cancer and Borderline Ovarian Tumors: Focus on Genomic and Proteomic Findings. *Current Genomics.* (10):240-249.
- Valadi, H. Ekstrom, K. Bossios, A. Sjostrand, M. Lee, J.J. and Lotvall, J.O. 2007. Exosome mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 9:654-659.

- Wang and Chen. 2014. Circulating miRNAs in cancer: from detection to Therapy. *Journal of Hematology & Oncology*. 7:86.
- Wang, G. Chen, H.W. Oktay, Y. Zhang, J. Allen, E.L. Smith, G.M. Fan, K.C. Hong, J.S. French, S.W. McCaffery, J.M. Lightowlers, R.N. Morse, H.C. Koehler, C.M. and Teitell, M.A. 2010. PNPASE regulates RNA import into mitochondria. *Cell*. 142:456-467.
- Wang, G.L. Jiang, B.H. Rue, E.A. and Semenza, G.L. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci. USA*. 92:5510-5514.
- Warner, D.R., Bhattacharjee, V., Yin, X., Singh, S., Mukhopadhyay, P., Pisano, M.M., Greene, R.M., 2004. Functional interaction between Smad, CREB binding protein, and p68 RNA helicase. *Biochem. Biophys. Res. Commun*. 324: 70-76.
- Wenger, R.H. Stiehl, D.P. and Camenisch, G. 2005. Integration of oxygen signaling at the consensus HRE. *Sci STKE rev*.12.
- Wiesener, M.S. Turley, H. Allen, W.E. Willam, C. Eckardt, K.U. Talks, K.L. Wood, S.M. Gatter, K.C. Harris, A.L. and Pugh, C.W. 1998. Induction of endothelial PAS domain protein-1 by hipoksia: characterization and comparison with hipoksia-inducible factor-1alpha. *Blood*. 92:2260-2268.
- Xenaki, G. Ontikatzte, T. Rajendran, R. Stratford, I.J. Dive, C. Krstic-Demonacos, M. and Demonacos, C. 2008. PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hipoksia. *Oncogene*. 27:5785-5796.
- Yang, W. Xia, Y. Ji, H. Zheng, Y. Liang, J. Huang, W. Gao, X. Aldape, K. and Lu, Z. 2011. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. *Nature*. 480:118-122.
- Yap, T.A. Carden, C.P. and Kaye, S.B. 2009. Beyond chemotherapy: targeted therapies in ovarian cancer. *Nat Rev Cancer*. 9:167-181.
- Zhang, H.T. 2013. microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. *Onco Rep*. 3-6.
- Zhang, J. Khvorostov, I. Hong, J.S. Oktay, Y. Vergnes, L. Nuebel, E. Wahjudi, P.N. Setoguchi, K. Wang, G. Do, A. Jung, H.J. McCaffery, J.M. Kurland, I.J. Reue, K. Lee, W.N. Koehler, C.M. and Teitell, M.A. 2011. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. *EMBO*. 30:4860-4873.

- Zhao, X. 2012. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. *Mol Med Rep.* 3-8.
- Zheng, S.R. Gui, L.G. Wei, Z. Guan, L.H. Xiao, Q. Jin, Z. Qi, D.H. Jie, Y. and Xiao, H.Z. 2012. Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. *Oncol Rep.* 27:1149-1155.
- Ziello, J.E. Jovin, I.S. and Huang, Y. 2007. Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and its Potential for Therapeutic Intervention in Malignancy and Ischemia. *JOURNAL OF BIOLOGY AND MEDICINE.* 80. pp.51-60.